<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-12201-2016025 - 2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Long-term neurological and neurocognitive outcomes of perinatally hiv-infected children, a case controle cohort (NOVICE)</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Despite combination antiretroviral therapy (cART), perinatally HIV (PHIV)-infected children present with significant neurodevelopmental delays and cognitive impairments. The pathogenesis may partially differ from that in adults, as HIV does not only cause direct injury to the CNS, but may also impede the development of the pediatric brain. As we have recently shown, manifestations of HIV in the pediatric central nervous system (CNS) include brain volume reduction and white matter lesions, as well as widespread microstructural changes, such as poorer white matter integrity and alterations in cerebral metabolites. Evidence implies significant roles for ongoing neuroinflammation, vascular dysfunction and hypercoagulability. Investigations combining neuropsychological assessment, multimodal neuroimaging and laboratory evaluation of inflammatory and neurodegenerative markers could greatly increase our understanding and improve treatment strategies. Longitudinal research will be crucial to observe and understand mechanisms underlying these long-term consequences of CNS exposure to HIV and cART as PHIV-infected survive into adulthood. In this study we will evaluate neurological and cognitive outcomes in a case-control cohort of PHIV infected children and sex, ethnicity and socioeconomic status matched healthy controls at an interval period of four years. We will investigate potential mechanisms and factors (such as inflammatory and neuronal biomarkers) that may influence these CNS functions.</narrative>
  </description>
  <description type="4">
   <narrative xml:lang="EN">Despite combination antiretroviral therapy (cART), perinatally HIV (PHIV)-infected children present with significant neurodevelopmental delays and cognitive impairments.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">With this study, we will compare for the first time neurological, neurocognitive outcomes with neuroradiological alterations and cART levels in CSF and blood while monitoring immune responses (i.e
inflammatory, coagulation, endothelial cell activation and neural damage markers) in CSF and blood in perinatally HIV- infected children in a longitudinal setting after an interval of 4 years. With this study we will be able to demonstrate alterations in the severity and nature of cerebral injury of perinatally HIV-infected children and alterations in underlying mechanisms.The results of this study may have direct implications on the pediatric hiv patient care. Research questions:
1. What are the long term neurological, ophtalmological and cognitive outcomes of perinatally hiv-infected children, that are stable on cART as compared to age, sex, ethnicity and socioeconomic status matched control group (NOVICE cohort) measured after an interval period of four years?
2. What is the expression of and association between CSF/blood biomarkers (such as cART levels, virological, inflammatory, endothelial cell activation and neuronal damage markers) and neurological, ophtalmological and cognitive outcome in hiv-infected children as compared to matched controls (NOVICE cohort) after an interval period of four years?
Outputs are scientific papers</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">scientific community
children with HIV</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-09-01" type="2"></activity-date>
  <activity-date iso-date="2020-09-01" type="4"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland</narrative>
   </organisation>
   <email>IATI@aidsfonds.nl</email>
   <website>https://aidsfonds.nl/</website>
   <mailing-address>
    <narrative xml:lang="EN">Aidsfonds - Soa Aids Nederland, Condensatorweg 54, 1014 AX Amsterdam</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">STD control including HIV/AIDS</narrative>
  </sector>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C48" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2016-09-01"></period-start>
   <period-end iso-date="2020-09-01"></period-end>
   <value currency="EUR" value-date="2016-09-01">498489</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-02-28"></transaction-date>
   <value currency="EUR" value-date="2017-02-28">55000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-02-28"></transaction-date>
   <value currency="EUR" value-date="2017-02-28">55000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-11-28"></transaction-date>
   <value currency="EUR" value-date="2017-11-28">55000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-11-28"></transaction-date>
   <value currency="EUR" value-date="2017-11-28">55000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2018-11-29"></transaction-date>
   <value currency="EUR" value-date="2018-11-29">55000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-11-29"></transaction-date>
   <value currency="EUR" value-date="2018-11-29">55000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-06-13"></transaction-date>
   <value currency="EUR" value-date="2021-06-13">110000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2021-06-14"></transaction-date>
   <value currency="EUR" value-date="2021-06-14">110000</value>
   <description>
    <narrative xml:lang="EN">Kpl CC403001</narrative>
   </description>
   <provider-org ref="NL-KVK-41207989" type="22">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVL-41204333">
    <narrative xml:lang="EN">AMC MR</narrative>
   </receiver-org>
  </transaction>
  <related-activity ref="NL-KVK-41207989-P-10706-2S4KN" type="1"></related-activity>
 </iati-activity>
</iati-activities>
